Capricor Therapeutics (CAPR) has signed a collaboration agreement and exclusive licensing option with Janssen Biotech (Janssen), a Johnson & Johnson company, for the development of new cardiovascular products.
Under the deal, both the firms agreed to collaborate on the development of Capricor’s cell therapy programme for cardiovascular applications, including its lead product, CAP-1002, an allogeneic cardiosphere-derived cell (CDC) therapeutic under evaluation in patients who have suffered a large myocardial infarction.
Following the deal, both companies will collaborate on elements of cell manufacturing development.
The deal will see Capricor contribute to the costs of the manufacturing collaboration and receive an upfront payment of $12.5m from Janssen.
As part of the deal, Janssen has the right to enter into an exclusive licence agreement for CAP-1002 at any time until 60 days after delivery by Capricor of the six-month follow-up results from Phase II of Capricor’s ALLSTAR clinical trial for CAP-1002.
Capricor will also be eligible to receive about $325m in additional payments, if Janssen exercises its option rights, as well as royalties that would be paid on commercial sales of CAP-1002.
Capricor CEO Linda Marban said the collaboration with Janssen is an important validation of the company’s lead product CAP-1002.
"We are proud to be working with Janssen to support the continued development of CAP-1002 and for the additional non-dilutive capital to further our research and development that will add to our pipeline," Marban said.
Capricor is mainly focused on the development of novel therapeutics to prevent and treat heart disease, has two leading product candidates including CAP-1002 and Cenderitide.
Image: Myocardial infarction of the tip of the anterior wall of the heart (2). Photo: courtesy of JHeuser.